Shares of Atara Biotherapeutics (ATRA) have gained 11.4% over the past four weeks to close the last trading session at $8.72, but there could still be a solid upside left in the stock if short-term ...
Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara ...
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics ...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients ...
LOS ANGELES, CA / ACCESS Newswire / February 12, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...
Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") . Such investors are advised to contact Danielle Peyton at ...
Atara Biotherapeutics has a fifty-two week low of $5.40 and a fifty-two week high of $39.50. Atara Biotherapeutics ( NASDAQ:ATRA – Get Free Report ) last posted its quarterly earnings results on ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that relies on harnessing patients' cancer-fighting capabilities. Though the ...
Atara Biotherapeutics, a biopharmaceutical company, disclosed plans to cut about half of its current employees. This decision comes in the wake of the Food and Drug Administration's (FDA) Complete ...